Total Payments
$137,132
2024 Payments
$30,183
Companies
13
Transactions
120
Medicare Patients
250
Medicare Billing
$171,369
Payment Breakdown by Category
Consulting$83,724 (61.1%)
Other$40,366 (29.4%)
Travel$9,533 (7.0%)
Food & Beverage$3,209 (2.3%)
Research$300.00 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $83,724 | 35 | 61.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $23,463 | 7 | 17.1% |
| Honoraria | $16,903 | 4 | 12.3% |
| Travel and Lodging | $9,533 | 22 | 7.0% |
| Food and Beverage | $3,209 | 51 | 2.3% |
| Unspecified | $300.00 | 1 | 0.2% |
Payments by Type
General
$136,832
119 transactions
Research
$300.00
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $77,544 | 59 | $0 (2024) |
| Chiesi USA, Inc. | $35,416 | 19 | $0 (2024) |
| Kyowa Kirin, Inc. | $8,815 | 8 | $0 (2024) |
| Amicus Therapeutics, Inc. | $7,108 | 7 | $0 (2023) |
| Baxter Healthcare | $5,765 | 10 | $0 (2024) |
| NxStage Medical, Inc. | $1,165 | 4 | $0 (2018) |
| Withings, Inc. | $586.74 | 1 | $0 (2023) |
| Covidien LP | $300.00 | 1 | $0 (2019) |
| Intuitive Surgical, Inc. | $135.39 | 2 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $126.86 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $30,183 | 29 | GENZYME CORPORATION ($11,448) |
| 2023 | $15,991 | 14 | Chiesi USA, Inc. ($7,745) |
| 2022 | $41,794 | 23 | GENZYME CORPORATION ($31,977) |
| 2021 | $12,895 | 6 | GENZYME CORPORATION ($9,593) |
| 2020 | $14,598 | 8 | Amicus Therapeutics, Inc. ($5,289) |
| 2019 | $13,783 | 25 | GENZYME CORPORATION ($13,282) |
| 2018 | $574.79 | 2 | GENZYME CORPORATION ($502.50) |
| 2017 | $7,313 | 13 | BAXTER HEALTHCARE ($5,593) |
All Payment Transactions
120 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Chiesi USA, Inc. | ELFABRIO (Drug) | Consulting Fee | Cash or cash equivalent | $3,396.00 | General |
| Category: ERT FOR FABRY DISEASE | ||||||
| 12/05/2024 | Chiesi USA, Inc. | ELFABRIO (Drug) | Honoraria | Cash or cash equivalent | $3,955.00 | General |
| Category: ERT FOR FABRY DISEASE | ||||||
| 12/05/2024 | Chiesi USA, Inc. | ELFABRIO (Drug) | Travel and Lodging | Cash or cash equivalent | $2,173.85 | General |
| Category: ERT FOR FABRY DISEASE | ||||||
| 11/21/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $17.86 | General |
| Category: Phosphate binder for ESRD | ||||||
| 11/04/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $43.66 | General |
| 10/26/2024 | Chiesi USA, Inc. | ELFABRIO (Drug) | Food and Beverage | Cash or cash equivalent | $28.58 | General |
| Category: ERT FOR FABRY DISEASE | ||||||
| 10/24/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $126.86 | General |
| Category: Immunology | ||||||
| 09/26/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $2,548.00 | General |
| 09/16/2024 | GENZYME CORPORATION | FABRAZYME (Biological) | Food and Beverage | In-kind items and services | $14.60 | General |
| Category: Genetic Disease | ||||||
| 09/12/2024 | GENZYME CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,438.00 | General |
| 08/21/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $19.82 | General |
| Category: Phosphate binder for ESRD | ||||||
| 08/20/2024 | Kyowa Kirin, Inc. | Crysvita (Drug) | Consulting Fee | Cash or cash equivalent | $7,700.00 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 08/10/2024 | Kyowa Kirin, Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 08/10/2024 | Kyowa Kirin, Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 08/10/2024 | Kyowa Kirin, Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 08/10/2024 | Kyowa Kirin, Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 08/09/2024 | Kyowa Kirin, Inc. | Crysvita (Drug) | Travel and Lodging | In-kind items and services | $619.30 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 08/09/2024 | Kyowa Kirin, Inc. | Crysvita (Drug) | Travel and Lodging | In-kind items and services | $226.86 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 08/09/2024 | Kyowa Kirin, Inc. | Crysvita (Drug) | Food and Beverage | In-kind items and services | $119.11 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 08/06/2024 | GENZYME CORPORATION | FABRAZYME (Biological) | Food and Beverage | In-kind items and services | $87.96 | General |
| Category: Genetic Disease | ||||||
| 07/17/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $14.22 | General |
| Category: Phosphate binder for ESRD | ||||||
| 06/01/2024 | GENZYME CORPORATION | FABRAZYME (Biological) | Consulting Fee | Cash or cash equivalent | $2,548.00 | General |
| Category: Genetic Disease | ||||||
| 05/20/2024 | GENZYME CORPORATION | FABRAZYME (Biological) | Food and Beverage | In-kind items and services | $31.06 | General |
| Category: Genetic Disease | ||||||
| 05/06/2024 | Baxter Healthcare | Renal - PD (Device) | Food and Beverage | In-kind items and services | $53.43 | General |
| Category: Renal | ||||||
| 04/17/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $18.32 | General |
| Category: Phosphate binder for ESRD | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 25 | 147 | $130,830 | $31,277 |
| 2022 | 1 | 26 | 187 | $166,430 | $43,122 |
| 2021 | 4 | 83 | 270 | $194,278 | $50,231 |
| 2020 | 5 | 116 | 319 | $221,353 | $46,740 |
Total Patients
250
Total Services
923
Medicare Billing
$171,369
Procedure Codes
11
All Medicare Procedures & Services
11 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90966 | Home dialysis services per month (20 years or older) | Office | 2023 | 25 | 147 | $130,830 | $31,277 | 23.9% |
| 90966 | Home dialysis services per month (20 years or older) | Office | 2022 | 26 | 187 | $166,430 | $43,122 | 25.9% |
| 90966 | Home dialysis services per month, patient 20 years of age or older | Office | 2021 | 34 | 194 | $172,660 | $45,131 | 26.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 18 | 23 | $6,831 | $1,862 | 27.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 18 | 30 | $6,300 | $1,681 | 26.7% |
| 90945 | Dialysis procedure including one evaluation | Facility | 2021 | 13 | 23 | $8,487 | $1,557 | 18.3% |
| 90966 | Home dialysis services per month, patient 20 years of age or older | Office | 2020 | 50 | 215 | $191,350 | $39,844 | 20.8% |
| 90945 | Dialysis procedure including one evaluation | Facility | 2020 | 19 | 32 | $11,808 | $2,179 | 18.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 16 | 25 | $7,425 | $2,060 | 27.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 17 | 25 | $6,150 | $1,391 | 22.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 14 | 22 | $4,620 | $1,266 | 27.4% |
About Eric Wallace
Eric Wallace is a Nephrology healthcare provider based in Birmingham, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/07/2007. The National Provider Identifier (NPI) number assigned to this provider is 1871706960.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Eric Wallace has received a total of $137,132 in payments from pharmaceutical and medical device companies, with $30,183 received in 2024. These payments were reported across 120 transactions from 13 companies. The most common payment nature is "Consulting Fee" ($83,724).
As a Medicare-enrolled provider, Wallace has provided services to 250 Medicare beneficiaries, totaling 923 services with total Medicare billing of $171,369. Data is available for 4 years (2020–2023), covering 11 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Other Specialties Nephrology, Nephrology
- Location Birmingham, AL
- Active Since 05/07/2007
- Last Updated 03/17/2025
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1871706960
Products in Payments
- FABRAZYME (Biological) $32,448
- ELFABRIO (Drug) $17,414
- FABRAZYME (Drug) $12,716
- Crysvita (Drug) $8,815
- Renal - Non Product Related (Biological) $5,550
- NO PRODUCT DISCUSSED (Drug) $1,368
- System One (Device) $1,165
- GZ402671 (Drug) $294.00
- Renal - PD (Device) $215.03
- GALAFOLD (Drug) $139.30
- Da Vinci Surgical System (Device) $135.39
- Fabhalta (Drug) $126.86
- Velphoro (Drug) $85.79
- Parsabiv (Biological) $50.00
- Auryxia (Drug) $20.55
- Sensipar (Drug) $12.56
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Birmingham
David Warnock, Md, MD
Nephrology — Payments: $186,004
Nephrology $186,004
Dana Rizk
Nephrology — Payments: $124,680
Nephrology $124,680
Michal Mrug
Nephrology — Payments: $92,833
Nephrology $92,833
Ashita Tolwani
Nephrology — Payments: $67,643
Nephrology $67,643
Timmy Lee
Nephrology — Payments: $38,311
Nephrology $38,311
Vineeta Kumar
Nephrology — Payments: $34,582
Nephrology $34,582